Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5-fluorouracil (5-FU); however, these studies have focused on European and European-American populations. Our laboratory recently demonstrated that additional variants in non-European haplotypes are predictive of 5-FU toxicity. The objective of this study was to identify potential risk variants in an understudied East African population relevant to our institution's catchment area. The DPYD protein-coding region was sequenced in 588 individuals of Somali or Kenyan ancestry living in central/southeast Minnesota. Twelve novel nonsynonymous variants were identified, seven of which significantly decreased DPD activity in vitro. The commonly reported toxicity-associated variants, *2A, D949V, and I560S, were not detected in any individuals. Overall, this study demonstrates a critical limitation in our knowledge of pharmacogenetic predictors of 5-FU toxicity, which has been based on clinical studies conducted in populations of limited diversity.
Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5-fluorouracil (5-FU); however, these studies have focused on European and European-American populations. Our laboratory recently demonstrated that additional variants in non-European haplotypes are predictive of 5-FU toxicity. The objective of this study was to identify potential risk variants in an understudied East African population relevant to our institution's catchment area. The DPYD protein-coding region was sequenced in 588 individuals of Somali or Kenyan ancestry living in central/southeast Minnesota. Twelve novel nonsynonymous variants were identified, seven of which significantly decreased DPD activity in vitro. The commonly reported toxicity-associated variants, *2A, D949V, and I560S, were not detected in any individuals. Overall, this study demonstrates a critical limitation in our knowledge of pharmacogenetic predictors of 5-FU toxicity, which has been based on clinical studies conducted in populations of limited diversity.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? þ Most clinical pharmacogenetic studies of 5-FU toxicity have focused on European and European American populations with only limited information from other racial groups.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ In this study, we examined the occurrence and frequency of DPYD variants in an East African population in our catchment area in central and southeastern Minnesota.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE þ The study identified novel DPYD variants that cause decreased DPD activity in this East African cohort and are potential risk alleles for 5-FU toxicity. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ Data from this study may provide valuable guidance for individualizing 5-FU therapy in East African patients with cancer.
Since it was introduced in 1957, 5-fluorouracil (5-FU) has become the cornerstone of chemotherapeutic regimens for a variety of solid tumors, primarily gastrointestinal, breast, and skin cancers. However, 5-FU has a narrow therapeutic index that contributes to the risk of dose limiting severe adverse toxicity, which affects 31-34% of treated patients. 1 The uracil catabolic pathway is responsible for degrading 85% of administered 5-FU. 2 Dihydropyrimidine dehydrogenase (DPD; encoded by DPYD) is the initial and ratelimiting enzyme of the uracil catabolism, and, as such, variability in DPD enzyme activity was shown to affect 5-FU metabolism and adverse toxicity. 3 A number of genetic variations in DPYD have been linked to 5-FU toxicity in several clinical studies. [4] [5] [6] [7] Therefore, *2A (rs3918290) has been associated with impaired DPD function and increased incidence of severe toxicity and death. 8, 9 Two additional variants, p.I560S (rs55886062) and p.D949V (rs67376798), have been consistently associated with toxicity. 9, 10 The intronic variant c.1129-5923C>G (rs750187182) has been linked to a toxicity-associated haplotype and was suggested to contribute to 5-FU toxicity through nonobligate alternative splicing of DPYD. 11, 12 Importantly, the clinical studies that identified and characterized these variants were comprised almost entirely of European or European-American patients.
Using a cohort of healthy African-American volunteers, our laboratory identified p.Y186C (rs115232898) as a potential risk variant for 5-FU-related toxicity. Carriers of p.Y186C had significantly reduced DPD enzyme activity in peripheral blood mononuclear cells. 13 The variant was subsequently detected in patients with 5-FU-related severe toxicity, 14 one potentially linked to lethality. 15 Notably, none of the toxic p.Y816C carriers presented with any other known toxicity-related variants. An analysis of publically available genotype databases suggested that p.Y186C may be carried as a haplotype associated with West African populations. 13 Recent genetic studies have suggested that Eastern and Saharan Africans have genetic components that are distinguished from population groups in western, central, and southern Africa. 16, 17 Therefore, we hypothesized that East African individuals may carry a distinct repertoire of DPYD variants that may confer the risk of 5-FU toxicity. As such, targeted genotyping for currently accepted 5-FU risk variants would not be expected to provide useful predictive information in individuals with East African ancestry. Our institution's catchment area houses some of the world's largest groups of people with East African origin outside of Africa. According to the American Community Survey Data on the Foreign-Born Population conducted by the United States Census Bureau between 2008 and 2012, Minnesota is home to the largest Somali population in the United States (17, 320) , and the second largest Kenyan (5,610), and Ethiopian (12, 905) populations. 18 Given the sizable number of East Africans in our catchment area, and the putative difference in DPYD risk alleles from other African populations, the objectives of the current study were to assess the distribution of known toxicity-associated variants within the understudied East African population, and to identify any novel deleterious DPYD variants in that group.
RESULTS

Performance and optimization of targeted sequencing strategy
Targeted sequencing of the coding region was performed in two sets. The first set was comprised of 270 individuals of Somali origin, whereas the second set included 278 Somali and 40 Kenyan participants ( Table 1 ). The first set had an average coverage of 4,000X, with 98.48% of target region covered. Data from the first set was used to improve sequence quality in low-quality areas and to increase the number of specimens being multiplexed per high throughput sequencing lane. The average coverage for the second set was 202X for Somalis and 180X for Kenyans. The target region was covered at 97.64% and 98.64% for the Somalis and Kenyans, respectively.
Identification of coding region variants in the DPYD gene A total of 588 individuals (548 Somalis and 40 Kenyans) participated in this study ( Table 1) . In all, 152 variants were identified. A summary of the reported variants is depicted in Figure 1a . Thirty-four variants were located in exons, 78 were located in exon-flanking regions, and 40 were located in the 5 0 and 3 0 untranslated regions. Of the exon variants, 16 were not present in the National Center for Biotechnology Information database of genetic variation (single-nucleotide polymorphism (SNP)) and were thus considered novel. 19 These novel variants included 12 nonsynonymous variants that are predicted to change one or more amino acids in DPD and 4 synonymous variants. Overall, 24 nonsynonymous variants were identified in Somalis and 9 in Kenyans ( Figure 1b) . Novel nonsynonymous variants included the frameshift variant p.I971N [FS] and the 9 nucleotide inframe duplication/insertion p.S14-S16[dup], as well as 10 single amino acid substitutions ( Table 2 ). The locations and genotype frequencies of novel nonsynonymous and synonymous variants are presented in Table 2 ; detected synonymous and nonsynonymous variants that have been previously reported in the database of SNPs are presented in Supplementary Table S1 online. Detected intron and untranslated region variants that have been previously reported in the database of SNPs are presented in Supplementary Table S2 online; novel intron and untranslated region variants that were detected in this study population are presented in Supplementary Table S3 online. Notably, none of the known 5-FU toxicity-associated DPYD variants *2A (rs3918290; also known as IVS1411G>A), p.I560S (rs55886062; also known as *13), or p.D949V (rs67376798) were detected in this study population ( Table 2) . No variants were detected within DPYD splice donor or acceptor sequences (data not shown). The genotype frequencies for all detected variants were found to be in HardyWeinberg equilibrium (P > 0.05). All the novel variants have minor allele frequencies of <1% ( Table 2) .
Effects of nonsynonymous variants on DPD enzyme activity
To assess the potential contribution of detected nonsynonymous variants to risk of 5-FU toxicity, we measured the in vitro DPD enzyme activity of all 12 novel nonsynonymous variants using a mammalian system of transgenic expression that was previously reported by our laboratory. 20, 21 Of the 12 variants tested, 7 showed significant reductions in DPD enzyme activity ( Figure 2 , respectively). The five additional novel nonsynonymous SNPs detected in the study population (p.R394Q, p.L523F, p.I528V, p.R699T, and p.S14-S16(dup)) did not significantly alter DPD function ( Figure 2 ). Our laboratory has previously determined the impact on DPD enzyme activity for many reported DPYD variants. 20, 21 A summary of the functional effects for variants detected in this study is included in Supplementary Table S1 online. Notably, two of these detected variants (p.Y186C and p.D342N) resulted in significant reductions in enzyme activity.
Structural considerations for novel variants
To investigate the mechanism(s) by which deleterious variants impaired DPD enzyme activity, the location of novel variants was modeled onto the pig DPD crystal structure ( Figure 3 ). An overview of the monomeric structural domains is shown in Figure 3a . The novel deleterious variant p.P86L is located within domain I (residues 27-172), near to one of the four 4Fe-4S clusters ( Figure 3b ). Domain II (residues 173-286 and 442-524) contains four benign novel variants (p.P237L, p.A513V, p.S14_S16(dup), and p.L523F; Figure 3c ). Three variants p.A513V, p.S14_S16 [dup] , and p.L523F are located in a nonstructural loop region; p.P237L is located at the beginning of a predicted alpha helical amino acid stretch. A single benign variant (p.R394Q) is located near the middle of a beta turn in domain III (residues 287-441; Figure 3d ). The deleterious p.T793I variant substitutes a polar uncharged threonine with a nonpolar, hydrophobic isoleucine near the uracil binding site within domain IV, which consists of residues 525-847 (Figure 3e) .
Two additional benign variants (p.I528V and p.R699T) are located in domain IV (Figure 3e) . The deleterious missense variant p.V941A is located three amino acids upstream from a beta turn that is in close proximity to the pair of 4Fe-4S clusters located within domain V, which consist of residues 1-26 and 848-1025 ( Figure 3f) . Likewise, sequences downstream of isoleucine 971, which are altered due to the p.I971 [FS] variant, are also in close proximity to the 4Fe-4S clusters in domain V (Figure 3f) . Finally, the moderately deleterious missense variant p.P1023T is located within a likely nonstructural domain near the C-terminal end of DPD, which has not been resolved by crystallography (Figure 3f ).
DISCUSSION
Numerous preclinical and clinical studies have established that certain DPYD variants can dramatically increase the risk of severe toxicity to 5-FU. The most intensively studied DPYD variant *2A disrupts the splice donor site at the 5 0 end of intron 14, leading to alternative splicing. This alternatively spliced product lacks exon 14 (an in-frame deletion) and functionally inactivates the enzyme. 22 The decreased levels of functional DPD led to reduced 5-FU catabolism and increased 5-FU availability for conversion into active metabolites via anabolism. 23 In turn, carriers of deleterious variants, such as *2A, are at increased risk for adverse toxicity to 5-FU. 8, 24 Two additional variants p.I560S and p.D949V have also been reported to be associated with toxicity. 8, 9, 24 Recently, a large clinical study was conducted to evaluate the association of these three variants with clinical adverse events and their predictive value in detecting toxicity; the study demonstrated a statistically significant association between two of the variants and the incidence of adverse toxicity events (grade 3 or more). 7 The third variant, p.I560S, is rare and the study lacked adequate power to conclusively assess this variant. These three variants are mainly detected in individuals of European ancestry, and less likely to be found in individuals of other racial groups (Figure 4a) . The Clinical Pharmacogenetics Implementation Consortium has recently issued a set of guidelines to provide dosing recommendations for 5-FU chemotherapy based on DPYD genotype limited to these aforementioned variants. 25 In the current study, we identified and characterized 12 novel nonsynonymous variants in individuals of East African ancestry.
Seven of these variants were found to be deleterious by in vitro measurement of recombinant DPD activity. Interestingly, the three known toxicity-associated variants, *2A, p.I560S, and p.D949V, were not detected in the study populations, which is consistent with allele frequency data obtained from the 1000 Genome Project (Figure 4a) . Benign nonsynonymous DPYD variants (Figure 4b ) and synonymous DPYD variants ( Figure 4c ) were detected at frequencies broadly consistent with the reported frequencies in the 1000 genome African super-population.
Our laboratory previously identified the p.Y186C variant in an African-American population. 13 Data from the 1000 Genomes Project, 26 confirms that this variant is mainly found in African populations, including Americans of African Ancestry in Southwest in the United States, Yoruba in Ibadan, Nigeria, and Luhya in Webuye, Kenya populations. In the present study, this variant was detected in a single Somali individual (0.2% allele frequency) and in three The potential effect of DPYD variants on the protein structure or function was predicted by Polymorphism Phenotyping-2 (PolyPhen-2), Sorting Intolerant From Tolerant (SIFT), and Protein Variation Effect Analyzer (PROVEAN). Qualitative predictors (benign, possibly damaging, and probably damaging for PolyPhen-2), (damaging and tolerated for SIFT) and (deleterious and neutral for PROVEAN) were reported by the software. In silico prediction scores were assigned as follows: 3 5 the variant was predicted as damaging/deleterious by all three programs; 2 5 the variant was predicted as damaging/deleterious by two programs; 1 5 the variant was predicted as damaging/deleterious by one program; 0 5 the variant was predicted as benign/neutral/tolerated. c *2A, I560S, and D949V are the most commonly reported DPYD variants that are known to be associated with 5-FU toxicity. They were not detected in this cohort. Kenyans (7.5% allele frequency). Ancestry mapping studies have suggested that Kenyan haplotypes contain predominantly Niger-Congo components (an ancestral component for some of West African haplotypes as well), whereas Somali from Somalia and Ethiopia haplotypes mainly belong to the Lowland East Cushitic ancestral component (which is more closely related to Middle eastern and European ancestral components). 17 These distinguishing ancestral components potentially explain the elevated frequency of p.Y186C in the Kenyan compared to Somali populations reported herein. The distinction in ancestral haplotypes may also partially explain the unique variants that were detected within the Kenyan (i.e., p. A721T) and Somali (i.e., p.P86L, p.P237L, p.R394Q, p.A513V, p.S14_S16dup, p.L523F, p.I528V, p.R699T, p.T793I, p.V941A, p.I971Nfs, p.K259E, p.G258S, p.D342N, p.S534N, and p.V812I) populations (Figure 1b) .
In addition to p.Y186C (discussed above), our laboratory previously determined that p.D342N, which was detected as a heterozygous allele in four Somali individuals in the present study, significantly impaired DPD function (17% relative DPD activity). 20 The variant p.V732I was detected in 64 East African individuals (MAF 5.7%; Supplementary Table S1 online). A previous in vitro study showed that this variant did not alter the enzyme function when compared to wild-type DPD. 21 Nevertheless, another study reported that African Americans who carried p.V732I had significant reduction in DPD enzyme activity but only in conjunction with p.Y186C. 13 This observation is further supported by the finding of a study that aimed to detect the I971Nfs  P86L  T793I  V941A  P1023S  A513V  P237L  R394Q  L523F  I528V R699T S14_S16dup Relative DPD activity ± SD DPD amino acid variant Figure 2 Relative dihydropyrimidine dehydrogenase (DPD) enzyme activity was determined in vitro for novel DPYD variants. For each variant, the horizontal bar represents the mean of four biologic replicates 6 SD. Each biologic replicate is the average of three technical replicates. The mean activity of wild-type DPYD, and *2A DPYD were used as positive and negative controls, respectively. The horizontal dashed lines represent the SD for wild-type DPYD. Numbers represent the P values for the respective deleterious variants compared against matched wild-type controls. correlation of this variant to 5-FU toxicity in a cohort of patients with colorectal cancer. 5 A recent study reported a statistically significant association of p.V732I with grade 3 or greater toxicities in a group of European patients. 27 Collectively, these findings may suggest that an additional variant in linkage disequilibrium with p.V732I may be contributing to DPD deficiency. Additional study of this variant and any variants in linkage disequilibrium with p.V732I will be needed to understand its contribution to 5-FU toxicity.
Of all variants detected in this study, the benign variant p.C29R was the most common with a minor allele frequency of 43.9% (T allele; Figure 4b and Supplementary Table S1 online). This frequency is similar to that reported for the 1000 Genome Project African super-population (T allele; 54.9%).
Interestingly, a previous study reported that p.C29R was found in a significantly higher frequency in low-toxicity compared to high toxicity groups of patients with colorectal cancer, indicating a putative protective effect of this variant. 5 Likewise, p.M166V, which was also detected in the East African cohort, showed what seemed to be a similar protective effect with a reduction in overall hematological adverse events and neutropenia. 5 However, the protective effect of p.M166V was questioned by another study that described an increased incidence of grades 3-4 5-FU toxicity in patients with gastroesophageal and breast cancer. 4 Previous studies suggested that genetic polymorphisms that are located outside of DPYD coding region or splice sites might also contribute to 5-FU toxicity. Among those is the deep intronic variant c.1129-5923C>G, which was found to create a cryptic splice donor site that resulted in an insertion of 44 bp fragment into the mature DPD mRNA. 12 An earlier study reported an association of a haplotype (HapB3) consisting of three intronic variants and a synonymous SNP, with severe 5-FU toxicity. 11 Notably, individuals with the deep intronic variant were not detected in the present study (data not shown), consistent with previous studies that suggested that this variant is mainly restricted to European haplotypes. 6, 12 Similarly, the complete HapB3 haplotype was not detected in any individuals in the present study.
Structurally, we found that the deleterious variants that severely affected enzyme function were generally located within domains that are important for protein function. The complete ablation of the enzyme function by the I971Nfs (located in domain V; Figure 3f ) could be explained by the altered structure that resulted from shifting of the reading frame. P86L was located close to one of the N-terminal Fe-S sites at domain I ( Figure 3b) ; therefore, it may disrupt function by interfering with electron shuttling. T793I changes the first of the three amino acids that constitute the binding site for flavin mononucleotide (FMN) at domain IV (Figure 3e ). This domain also includes the uracil-binding site. Altering the protein structure at this sensitive location could interfere with the binding of these nucleotides, and thus ablate enzyme function. Both V941A and P1023S are located within domain V in the vicinity of the C-terminal Fe-S sites (Figure 3f) . Their moderate effect on protein function could be explained by changing the protein structure and the microenvironment surrounding the Fe-S clusters. Of note, A513V and P237L were found to have a marginal effect on enzyme function. Their locations relative to the FADbinding site in domain II could possibly contribute to this minimal effect (Figure 3c) . Surprisingly, the three amino acid duplication S14_S16dup did not significantly affect enzyme function. This unexpected finding might be explained by its location in a flexible loop region at the periphery of the protein structure, which is distal from sites critical for enzyme function (Figure 3c) .
Although participants in the present study were not first-degree relatives based on individual and community discussions and questionnaires, we cannot rule out relatedness as a potential contributor to the allele frequencies noted for some variants. Regardless, the findings of the present study highlight the need for further evaluation of the distribution and frequency of DPYD variants in diverse populations. Furthermore, clinical studies are needed to evaluate the importance of these variants in predicting the toxicity and adverse events associated with 5-FU therapy.
In conclusion, this study presents a set of novel DPYD variants that were detected in East Africans. Some of the identified variants severely affected DPD enzyme function in vitro and could potentially contribute to 5-FU toxicity risk. This study also highlights the lack of known toxicity-associated variants (*2A, I560S, and D949V) in this population. The genetic predictive tests of 5-FU toxicity that are recommended for clinical use currently focus only on the aforementioned risk alleles. Based on the findings of this paper, these tests are likely of limited value for East African populations. The findings of this study will support the effort of achieving an individualized 5-FU therapy in patients with cancer of non-European ancestry.
MATERIALS AND METHODS Study participants
Samples were collected from healthy volunteers of East African origin with ancestry from Somalia or Kenya who were over 18 years of age. Ancestry was self-declared by study participants. Samples were collected in the Rochester, MN, Mankato, MN, and Minneapolis/St. Paul, MM, metropolitan areas. This study was approved by the Mayo Clinic Institutional Review Board. Individual consent was obtained from each study participant.
Targeted sequencing of DPYD Sequencing libraries were prepared using the Access Array System (Fluidigm, South San Francisco, CA). Custom primer panels were designed to cover all 23 exons of the DPYD gene, including untranslated region regions, using the Fluidigm D3 design portal. Target amplification was performed in parallel for 48 volunteers on a single Access Array chip. Samples from up to 10 chips were barcoded and pooled according to the manufacturer's protocol. Libraries were prepared using two separate iterations of the primer design. The first design (set A) was used to amplify 270 samples (all Somali). Samples were sequenced using an Illumina MiSeq (Illumina, San Diego, CA) by the Mayo Clinic Cancer Center Gene Analysis Shared Resource in the Mayo Clinic Advanced Genomics Technology Center. Sequence quality and depth of coverage was assessed for all 270 samples. Additional tiled primers were designed and added to the primer panels to compensate for regions of low quality sequencing or poor coverage. An additional 318 samples (278 Somali and 40 Kenyan) were amplified using the redesigned primer pools and sequenced. To confirm the sequence of identified variants, exons containing novel and/ or deleterious variants were amplified and sequenced using the Sanger method, as previously described 28 by the Mayo Clinic Cancer Center Gene Analysis Shared Resource. Insertion variants were additionally confirmed by cloning the polymerase chain reaction product into the pJET1.2/blunt vector (Thermo Scientific, Waltham, MA) and Sanger sequencing of multiple vector clones.
Expression vector construction
Plasmids with the specific variants were created using site-directed mutagenesis, as described previously. 21 Plasmid sequences were confirmed by the Mayo Clinic Cancer Center Gene Analysis Shared Resource in the Mayo Clinic Advanced Genomics Technology Center. Primers used for sitedirected mutagenesis are shown in Supplementary Table S4 online.
Cell lines and transfection HEK293T/c17 cells, which do no not express detectible DPD, 21 were acquired from the American Type Culture Collection and cultured, as previously detailed. 21 Low passage stocks were prepared after receipt and cells were maintained in culture media for a maximum of 10 total passages after receipt. The cells were regularly monitored by microscopy to confirm cell identity by monitoring cell morphology. Mycoplasm screening was performed every 3 months or whenever a question of contamination arose by using the mycoplasma detection kit PlasmoTest (InvivoGen, San Diego, CA). Additionally, cell proliferation was periodically monitored using real-time cell analysis (xCelligence RTCA System, Acea Biosciences, San Diego, CA). For transfection, 1 3 10 6 cells were seeded in 6-well plates containing Dulbecco's Modified Eagle's Medium (Mediatech, Manassas, VA) supplemented with 10% fetal bovine serum (Denville Scientific, Holliston, MA) and 1% L. glutamine (Thermo Scientific, Waltham, MA) at 378C for 24 h prior to transfection. Cells were transfected using XtremeGENE HP (Roche Diagnostics, Indianapolis, IN) per the manufacturer's protocol. Media was replaced after 24 h, and protein lysates were prepared 48 h after transfection, as described previously. 21 Experimental design for DPD enzyme activity assay Variants to be studied were randomly divided into three groups of four variants each. Each group was assessed in parallel with vectors encoding wild-type DPYD (positive control) and *2A (negative control). Data from three technical replicates (i.e., samples transfected and analyzed in parallel) were pooled to form a single biological replicate. Analyses were repeated for four independent biological replicates. Statistical analyses presented represent the variability between biological replicates. In vitro DPD activity was assessed, as detailed previously. 20 Briefly, protein lysates were incubated with nicotinamide adenine dinucleotide phosphate and C-14 labeled 5-FU. The conversion of C 14 5-FU to C 14 5-dihydrofluorouracil (C 14 ) was assessed using reverse-phase high-performance liquid chromatography. DPD activity was measured by calculating the area under the curve (AUC) for 5-dihydrofluorouracil compared to the total AUC for the combination of 5-FU and 5-dihydrofluorouracil using Dionex Chromeleon 7.1 Chromatography Data System software (Thermo Fisher Scientific, Waltham, MA). Expression of recombinant DPD variants was assessed, as detailed previously. 20 To minimize variability due to small differences in expression, activity was normalized to DPD expression, and relative activity of each variant relative to wild-type DPD is presented.
In silico functional prediction
The impact of the variants and the subsequent amino acid change on the biological function of DPD protein was predicted using PolyPhen-2 web server version 2.2.2, 29 SIFT version 4.0.3, 30 and Protein Variation Effect Analyzer (PROVEAN) version 1.1.3. 31 PolyPhen-2 software reports the results of the prediction as qualitative terms ("benign," "possibly damaging," and "probably damaging"), based on the false-positive rate estimated for each variant. SIFT prediction can either be "damaging" or "tolerated," depending on whether the variant affects the protein function or not, whereas PROVEAN reports either "deleterious" or "neutral."
Protein modeling UCSF Chimera version 1.10.2 was used to model the protein sequence and generate 3D images. 32 Variants were mapped on the porcine DPD crystal structure (PDBID 1GTH), which has 98% homology to human DPD. 33 
Statistical analysis
Statistical analyses were performed using JMP Pro 11.2.1 (SAS Institute, Minneapolis, MN).
Additional Supporting Information may be found in the online version of this article.
